Small Cap Wrap – Thalassa, Mailbox REIT PLC, Nexus Infrastructure and more…


Thalassa (LON:THAL) today announced that the Prospectus for the listing of the ordinary shares of its subsidiary Anemoi on the Standard Segment of the Official List and the LSE’s Main Market for listed securities has been approved by the UK Listing Authority  and will be posted today, 19 October 2020, on its website at ‎https://anemoi-international.com/investor-relations/ company-‎documents/‎.

23 Oct 2020

@HybridanLLP

 

*A corporate client of Hybridan LLP

 

Dish of the day

No Joiners Today

 

Off the menu

No Leavers Today

 

What’s cooking in the IPO kitchen?

Thalassa (LON:THAL) today announced that the Prospectus for the listing of the ordinary shares of its subsidiary Anemoi on the Standard Segment of the Official List and the LSE’s Main Market for listed securities has been approved by the UK Listing Authority  and will be posted today, 19 October 2020, on its website at ‎https://anemoi-international.com/investor-relations/ company-‎documents/‎. Application for Admission is being made to the UKLA and, subject to the UKLA’s approval, Anemoi expects that Admission will become effective and that unconditional dealings in the Shares will commence at 08.00 a.m. on 26, October 2020 under the ticker “AMOI”.

Verici DX—developer of advanced clinical diagnostics for organ transplant, intends to apply to have its issued share capital, as enlarged by a proposed placing, subscription . The Restricted Offer is only available to certain persons, being persons who held the beneficial title to any A Shares of £0.001 each in the capital of the Company on 10 July 2020 (the “Record Date”) whose registered address is in the UK  (being persons recorded on the register of members of Renalytix AI plc on 9 July 2020). £14.5m fundraise. Mkt Cap c.£28.3m. Due 3 November

SourceBio International to list on AIM. Offer TBC.  Due 29 Oct. Press reports suggest raise of up to £35m.  Services include Healthcare Diagnostics, Genomics, Stability Storage and infectious Disease Testing – since May 2020, the Group has provided COVID-19 Antigen RT-PCR testing services.

SDIC Holdings a leading power generation company in China is to list on the standard segment of the Official List and to trading on the Shanghai-London Stock Connect segment of the main market for listed securities of London Stock Exchange. Due on or around 22 Oct. Gross proceeds from the Offering are expected to amount to between approximately USD 220 million and USD 240 million. The proceeds will be used for expanding the Group’s renewable energy business overseas and repaying the Group’s offshore indebtedness.

Round Hill Music Royalty fund to IPO on the Specialist Fund Segment of the Main Market of the London Stock Exchange, by way of a placing and offer for subscription targeting the issue of 375 million ordinary shares  at an issue price of US$1.00 per Ordinary Share.  The Company’s Investment Objective is to provide investors with an attractive level of regular and growing income and capital returns from investment primarily in high quality, music intellectual property.  Due mid-November.

Meritwell II intends to list on the Specialist Funds Segment of the LSE raising up to £250m. The Placing will provide UK institutions with the opportunity to “swap” illiquid holdings which have become time and resource consuming holdings, at their bid price, in return for ordinary shares in the Company. Due 26 Oct.

Mailbox REIT PLC , a newly formed single asset company which owns the Mailbox , a large prime office-led mixed use property in Birmingham which has been independently valued at £179m, announced its intention to raise up to £62.5m  MailBox REIT  will apply for the Ordinary Shares be admitted to trading  on the IPSX Prime segment of International Property Securities Exchange (IPSX ).   IPSX is a new Regulated Investment Exchange regulated by the FCA and is the world’s first such exchange dedicated to the initial public offering and secondary market trading of companies owning single institutional grade real estate assets and multiple assets with commonality. Due  November.

Tirupati Graphite, the fully-integrated, cash generative, specialist graphite and graphene producer with operations in Madagascar and India, announced its potential intention to undertake an initial public offering on the LSE (standard listing). Timing tbc

Buffettology Smaller Companies Investment Trust— Buffettology is seeking to raise a minimum of £100m via an initial placing, an offer for subscription and an intermediaries offer on the Main Market. will be the Investment Manager to the Company, led by Keith Ashworth-Lord (CIO of Sanford Deland Asset Management Limited). Sanford DeLand manages approximately £1.4bn across two open ended funds, the CFP SDL UK Buffettology Fund and the Free Spirit® Fund.  Due 29 October.

Wheaton precious Metals (TSE:WPM) – Proposed secondary listing on bringing one of the world’s largest precious metal streaming companies to the London Stock Exchange. Due Q4 2020.

Umuthi Healthcare Solutions Plc, the technology led healthcare business focused on the distribution of pharmaceuticals and the provision of medical facilities in remote areas, seeking admission to the Standard Listing segment of the Official List.  Timing tbc

Kibo Energy PLC, the multi-asset Africa focused energy Company, is seeking admission for its 100% owned UK subsidiary Sloane Developments Ltd , which will be renamed Mast Energy Developments PLC (MED), to the Standard List of the London Stock Exchange plc. Targeted for Q4 2020. The MED business strategy is to acquire and develop a portfolio of flexible small-scale power generation assets, exploiting a growth niche market in the UK for Reserve Power generation to balance out the national grid at critical times.  

 

Banquet Buffet

Nexus Infrastructure 130p  £58.8m (LON:NEXS)

The provider of essential infrastructure services, utilities connections and smart energy infrastructure, announces a trading update ahead of its annual results for the financial year ended 30 September 2020, which will be announced on 11 December 2020.As expected, trading in the second half of the year has been severely impacted by the Covid-19 pandemic. The majority of sites were reopened by July and the recovery in activity levels since then has been encouraging, but significantly lower than the first half of the year. Of our three businesses, Tamdown has been most impacted by the continued uncertain macroeconomic backdrop and the implementation of additional health and safety procedures. This lower level of activity during the Group’s traditionally strong trading period has, as expected, resulted in the Group being loss making in the second half of the year. As a result, Nexus will report a loss before tax for the year ended 30 September 2020 albeit at an improved level from the Board’s expectations at the time of the Company’s equity issue in June.

The Group’s order book has reduced 17% year on year but overall remains strong at £282.0m (2019: £338.9m).   The Group’s strong balance sheet has been maintained, assisted by the successful equity issue in June this year, with a high cash and cash equivalent balance of £32.1m (2019: £27.4m) and net cash balance (after bank borrowings and finance leases) of £19.2m (2019: £18.0m ) The Board believes that the Group is in a strong position to deliver organic growth, aided by the structural undersupply in the UK housebuilding market and Government stimulus for the sector. 

 

Nucleus Financial Group 122.5p  £93.68m (LON:NUC)

The independent wrap platform provider, today publishes an update on its assets under administration (AUA) in respect of the three months to 30 September 2020. Despite the ongoing impact of Covid-19 on investor sentiment and market growth, the Company has continued to increase AUA, which stood at £16.1bn at 30 September 2020, up 1.8% on the previous quarter and 2.6% year-on-year. By comparison, the FTSE All-Share Index decreased 3.8% on the last quarter and fell by 19.2% year-on-year.

 

ITM Power 255p  £1.2bn (LON:ITM)

Results of placing and open offer.  Aggregate gross proceeds of approximately £165 million  at 235p.  The net proceeds of the Fundraising will be used by the Group principally to enable an acceleration of the Group’s technology, manufacturing and operational capabilities in response to the rapidly growing global demand for large-scale electrolysis, particularly:

 · £47 million to accelerate the Group’s development and production of large scale 5MW electrolyser stack platforms and modular 20MW electrolyser trains;

· £37 million to accelerate product standardisation and maximisation of manufacturing capacity at the Group’s Bessemer Park facility, and to support the potential future development of a new European gigafactory should additional future manufacturing capacity be required;

· £32 million to invest in the group’s operational capabilities, including developing the Group’s after-sales support and commissioning functions; and

· £30 million for the injection of funding into ITM Power’s refuelling division in order to identify and develop potential new large-MW capacity refuelling hubs

 

Sensyne Health 99.5p  £128m (LON:SENS)

The UK Clinical AI company, today announces it has signed a research collaboration agreement with Bristol Myers Squibb .  Initially the collaboration will focus on applying Sensyne’s proprietary machine learning to conduct research into disease progression and patient stratification for patients with various diseases within the broader group of Myeloproliferative Neoplasms (“MPNs”). MPNs comprise a group of rare blood diseases characterised by the overproduction of one or more types of blood cells – red blood cells, white blood cells and platelets.   The collaboration will be Sensyne Health’s fourth successive partnership with a major pharmaceutical company following collaborations signed with Bayer, Roche and Alexion. No financial terms have been disclosed.

 

All Active Asset Capital 8.55p  £67.5m (LON:AAA)

The Company has conditionally raised gross proceeds of £11.5 million through a placing of 143.75 million new ordinary shares  at an issue price of 8p  per share. The Company is actively seeking opportunities within the global technology, software and AI space, enabling it to provide investors with a distinct portfolio of tomorrow’s new market leaders.

 

Vianet Group 67p  £19.4m (LON:VNET)

“The international provider of actionable data and business insight through devices connected to its Internet of Things (“IOT”) platform, today announces the following trading update and notifies that it will release its results for the half year ended 30 September 2020 on Tuesday, 8 December 2020.

 The Group is pleased to report that trading for the first half of the current financial year has been ahead of our COVID-19-revised (“C-19”) management forecasts. There has been month-on-month improvement in operating profit and cash since the start of the financial year with September moving into profit.  Whilst the C-19 situation remains difficult to predict, the Group is in a robust financial and operating position to navigate FY2021 and continue the solid momentum that was building prior to C-19 and deliver on the exciting growth opportunities that we see ahead of us.”

 

The Barkby Group 18.75p  £25.4m (LON:BARK)

Barkby, the diversified business group, announced that its subsidiary Cambridge Sleep Sciences Ltd has launched its brand-new product, SleepHub™, a device which improves and facilitates natural sleep. 

SleepHub™is designed to help restore natural sleep cycles and improve wellbeing by using rhythms and pulses to emulate brain waves produced during sleep.

The product will retail at £599 per unit in the UK and is now available online at sleephub.com, and through selected partners. Sleep technology is an increasing area of focus and a growth area in the wider holistic wellness space which Cambridge Sleep Sciences Ltd is aiming to be at the forefront of.

Cambridge Sleep Sciences Ltd is in advanced discussions with a number of major retailers who are interested in stocking the product and we will update shareholders on progress in due course. 

 

Pan African Resources 20.65p  £398.2m (LON:PAF)

The Company’s American Depository Receipt (“ADR”) programme has been upgraded and approved to trade on the OTCQX Best Market (“OTCQX Market”) in the United States of America, with effect from 23 October 2020.

Pan African’s CEO, Cobus Loots said: “We are pleased to be admitted to the OTCQX Market, which is the highest tier of the OTC market. To qualify, Pan African has complied with the OTCQX Market requirements including high financial standards, corporate governance requirements, and compliance with applicable securities laws. Trading on the OTCQX Market will significantly enhance our visibility and provide better access to US investors”.

Pan African Resources is a mid-tier African-focused gold producer with a production capacity in excess of 1700,00oz of gold per annum.

 

Tectonic Gold  0.85p  £7.17m (AQSE:TTAU)

Preliminary costean sampling results from the site preparation for the drilling program at the Specimen Hill Prospect in Queensland, Australia. 

Drill rig access roads cut and drill pad preparation completed. Costeans cut on drill pads to expose fresh rock at surface mineralisation

Sampling has returned assays of +3.5g.t. Gold and +45g.y Silver

During the past few weeks our field team in Queensland were preparing access tracks and drill pads for the drilling campaign. This involves earthworks, utilising a bulldozer to clear tracks and establish level pads at each location to situate the drilling rig. In clearing the pads the team utilised the bulldozer to cut some shallow costeans into the identified mineralisation at surface to expose fresh rock. Samples were taken from these mineralised features and assayed to provide confirmation on targeting for the drilling. The campaign is designed to test grade at depth below this identified and tested surface mineralisation.

 

Beowulf Mining  6.15p  £39.15m (LON:BEM)

Results from an Induced Polarisation (“IP”) and resistivity survey undertaken by Vardar Minerals (“Vardar”) at its Wolf Mountain lead-zinc-silver (“Pb-Zn-Ag”) target, situated within the Mitrovica licence, located in northern Kosovo.  Beowulf owns 46.1 per cent of Vardar.

· Highly anomalous IP chargeability zones, considered high priority targets for drill testing, have been defined beneath areas of laterally extensive Pb-Zn gossans and hydrothermal alteration.

· The IP anomalies are located below, often straddling, the contact between younger Oligo-Miocene (“O-M”) volcanoclastic rocks and ultramafic (“UM”) basement, in agreement with mapped and drill tested mineralisation, adding further support for a source of the observed mineralisation.

· Importantly, anomalies follow established regional structural trends suggesting they may be representative of high-grade Pb-Zn-Ag feeder structures, often a characteristic of the deposit type.

· Resistivity results correlate very well with geological mapping, drilling and trenching, delineating the lateral and vertical extent of the low resistivity volcanoclastic units over the higher resistivity UM basement.

· Vardar is now planning a follow-up drilling programme to test the main anomalies for high-grade mineralisation.

If you would like to unsubscribe, please email [email protected] with “unsubscribe me”.

 

Head Chef

Derren Nathan

0203 764 2344

[email protected]

Status of this Note and Disclaimer

This document has been issued to you by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific entity and is not a personal recommendation to anyone. Recipients should make their own investment decisions based upon their own financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.

The information contained in this document is based on materials and sources that are believed to be reliable; however, they have not been independently verified and are not guaranteed as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information in this document nor should it be relied upon as such.

Any and all opinions expressed are current opinions as of the date appearing on this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.

This document is sent to you as market commentary only. As market commentary this document does not constitute any of (i) investment research and financial analysis or other forms of general recommendation relating to transactions in financial instruments for the purposes of section B of annex I to Directive 2014/65/EU (“MIFID II Directive”); or (ii) investment research as defined in article 36(1) of Commission Delegated Regulation 2017/565/EU made pursuant to the MIFID II              Directive; or (iii) non-independent research (as such term is defined in the Financial Conduct Authority’s Conduct of Business Sourcebook).

This document should not be relied upon as being an independent or impartial view of the subject matter. The individuals who prepared this document may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.

In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii)  persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority’s Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as “relevant persons”). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority’s Conduct of Business Sourcebook.

Neither this document nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.

Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.

This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.

Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.



Source link

Add a Comment